Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Snake venom launders out all stains

Purveyors of snake oil and its mythical powers may not have had it all wrong, if preliminary findings with the Florida cottonmouth, bloodstains and a washing machine stay on target. An enzyme extracted from the viper's venom appears to help launder out notoriously stubborn blood spots on clothing.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

Growth factor protein succeeds in growing new coronary arteries

Three patients of the UC Heart & Vascular Center have grown new coronary artery branches to increase blood flow to the heart after receiving a new growth factor protein (FGF1) in November 2003. All three patients showed improved blood flow to the heart twelve weeks following the injection.

26 Mar 2004

Children with sickle cell disease are living longer, dying less often from their disease

Children with sickle cell disease, an inherited red blood-cell disorder, are living longer, dying less often from their disease and contracting fewer fatal infections than ever before, researchers at UT Southwestern Medical Center at Dallas report. Their study, which will appear in the June edition of the scientific journal Blood, is the first to evaluate survival rates of children receiving the most modern treatments for sickle cell disease. It's also one of the largest published sickle cell studies to date. Researchers followed more than 700 Dallas-area children with the disease over two decades.

25 Mar 2004

Researchers turn off individual human genes to study their function

Researchers have produced vast libraries of short segments of ribonucleic acid (RNA) that can be used to turn off individual human and mouse genes to study their function. The libraries will be made widely available to laboratories studying human biology and disease. The researchers are optimistic that the libraries will become a powerful research tool for gene analysis and discovery.

25 Mar 2004

£5m for HIV/AIDS trial involving HIV patients in London, Moscow, South Africa and Australia

A joint Oxford University/Imperial College research programme into HIV/AIDS has received £5 million support from the Wellcome Trust to carry out a drug trial involving HIV patients in London, Moscow, South Africa and Australia.

24 Mar 2004

First US Tests of Bird-Flu Vaccine in Humans

Doctors are beginning the first test in the United States of a vaccine designed to protect people against one form of bird flu should an outbreak of the virus occur in humans. While the vaccine under study is not designed to protect against the precise bird-flu virus causing the current outbreak in poultry and in people, scientists will learn whether it protects against another strain of the virus that infects birds and people.

24 Mar 2004

20% of worldwide population lack enough zinc in diet

Up to one-fifth of the world's people lack sufficient zinc in their diet, while an estimated one-third live in countries considered at high risk of zinc deficiency, warns a comprehensive new report by an international group of medical researchers.

23 Mar 2004

Japan injects funds into fight against Bird Flu

Japan will support Cambodia, Indonesia, Laos and Viet Nam with $1.6 million in the fight against avian influenza, FAO announced today.

23 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

New research may help prevent anthrax, bubonic plague and typhoid fever

The mechanism used by the bacteria that cause anthrax, bubonic plague and typhoid fever to avoid detection and destruction by the body’s normal immune response, leading to life-threatening bacterial infections, has been identified by researchers at the University of California, San Diego (UCSD) School of Medicine.

22 Mar 2004

Japanese study raises concerns for childhood health issues

The number of children suffering from mental disorders and health problems such as allergies and asthma has risen sharply over the past decade in this country. The United States and European countries are also facing the increasingly serious problems of premature births and childhood obesity, in addition to allergic reactions. Many experts say the rise in health problems involving children is related to the use of chemicals in our daily lives and the impact of medical treatment provided to the children's mothers.

22 Mar 2004